Galapagos Valuation

Is GXEA undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of GXEA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate GXEA's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate GXEA's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for GXEA?

Key metric: As GXEA is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for GXEA. This is calculated by dividing GXEA's market cap by their current revenue.
What is GXEA's PS Ratio?
PS Ratio	6.6x
Sales	€260.09m
Market Cap	€1.72b

GXEA key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	n/a
Enterprise Value/EBITDA	n/a
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does GXEA's PS Ratio compare to its peers?

The above table shows the PS ratio for GXEA vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	7.6x
BIO3 Biotest	1.5x	3.6%	€1.4b
FYB Formycon	14x	33.4%	€848.4m
HPHA Heidelberg Pharma	12x	16.6%	€102.1m
MDG1 Medigene	3x	16.1%	€22.5m
GXEA Galapagos	6.6x	3.9%	€1.7b

Price-To-Sales vs Peers: GXEA is good value based on its Price-To-Sales Ratio (6.6x) compared to the peer average (7.6x).

Price to Sales Ratio vs Industry

How does GXEA's PS Ratio compare vs other companies in the DE Biotechs Industry?

6 Companies	Price / Sales	Estimated Growth	Market Cap
CNW co.don	0.7x	n/a	US$6.97m
V9Z Aceragen	0.4x	n/a	US$3.12m
PA8 Paion	0.2x	30.2%	US$2.78m
V9Z Aceragen	0.3x	-161.8%	US$2.18m

6 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: GXEA is good value based on its Price-To-Sales Ratio (6.6x) compared to the European Biotechs industry average (8.1x).

Price to Sales Ratio vs Fair Ratio

What is GXEA's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

GXEA PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	6.6x
Fair PS Ratio	1.2x

Price-To-Sales vs Fair Ratio: GXEA is expensive based on its Price-To-Sales Ratio (6.6x) compared to the estimated Fair Price-To-Sales Ratio (1.2x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Aspen Pharmacare Holdings

R74.3b

Manufactures and supplies specialty and branded pharmaceutical products worldwide.

LDZA

R9.00

0.6%

5.3%

Pharming Group

€492.8m

A biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally.

PHGN

€0.71

0.4%

-33.2%

Almirall

€1.8b

A biopharmaceutical company, engages in the purchase, manufacture, storage, and sale of skin-health medicines in Europe, the Middle East, the United States, Asia, and Africa.

E2Z

€8.45

1.1%

2.9%